| I NT ROD UCTI ON
Therapeutic plasma exchange (TPE) is used to treat a wide variety of conditions in heterogeneous patient populations. In this process, whole blood is removed from a subject and separated into components (red blood cells, white blood cells, platelets, and plasma) extracorporeally, thus enabling removal of the plasma with reinfusion of the other components back into the subject along with replacement fluids. The TPE process, by removing plasma and a portion of intravascular medications, may significantly alter the hemostatic milieu of the patient after the procedure. If the underlying medical condition, current medications, and various TPE technical parameters are not managed appropriately, the patient may be at risk for hemostatic complications that may lead to increased morbidity and even mortality. 1, 2 Despite the importance of these clinical decisions, there are relatively few guidelines published for managing hemostatic parameters in individuals undergoing TPE. A practice survey performed by Zantek et al. 3 demonstrated that there is wide variation in hemostasis management associated with TPE treatments among institutions.
In this article, we review clinical considerations for the optimal management of patients undergoing TPE from a practical hemostatic perspective, including scheduling of successive TPE procedures, options for monitoring coagulation status and how these laboratory values might help guide the choice of replacement fluids, calcium supplementation during apheresis when citrate is used as an extracorporeal circuit anticoagulant, and how medications could alter coagulation in the apheresis patient.
| M ATE RI ALS AN D ME THO DS
Ten physicians in the active practice of apheresis from eight institutions representing different geographic locations within the United States discussed how they manage anticoagulation issues in patients undergoing TPE. Additionally, results from a review of the pertinent literature are presented, including prior practice surveys. 3, 4 The data presented here were reviewed by all of the authors and represent a consensus.
| R ES ULT S

| TPE schedule and replacement fluids
For some conditions treated with TPE, such as thrombotic thrombocytopenic purpura (TTP), daily treatment usually is required. For many other indications listed in the American Society for Apheresis "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice," an "every-other-day" treatment schedule commonly is recommended. 5 Ideally, the apheresis team works closely with the patient's primary clinical team to determine a treatment schedule that not only allows for maximum efficacy of TPE but also minimizes the use of donor plasma as a replacement fluid. While there have been great strides in increasing the safety profile of blood products, there is still inherent risk in the transfusion of blood products. Laboratory values as well as the medical condition(s) of the patient help to guide practice in this context. For example, a patient with intracranial hemorrhage should be kept under tighter hemostatic control than an ambulatory patient with no active bleeding or recent or upcoming invasive procedures. A common scenario encountered in the TPE patient population is that the patient recently has had or soon will be scheduled for a biopsy or other invasive intervention. This patient requires special attention to the maintenance of hemostasis, as a temporary decline in clotting factors may lead to destabilization of clots and a predisposition to bleeding.
Laboratory tests that help to guide replacement fluid choice may include the international normalized ratio (INR) or prothrombin time (PT) and fibrinogen. The activated partial thromboplastin time (aPTT) could also be used but is subject to variability, especially if the patient has been exposed to heparin. Coagulation factors are expected to decline when 5% albumin is used as the sole replacement fluid and thus the authors recommend that INR values of >1.5 to 2.0 or a fibrinogen value of <100 mg/dL prior to apheresis ordinarily indicate the need for use of at least some plasma during TPE, which typically is given during the last part of the procedure. 6 Because transfused plasma has vari- 10 Following a typical single plasma volume exchange using albumin replacement, most coagulation factor activity is close to pre-TPE levels within 24 to 48 h of the procedure, with the exception of fibrinogen, which is at 65% of pre-TPE levels at 48 h. 11, 12 In the pediatric population, similar hemostatic changes were observed as in adults. A retrospective study of 35 pediatric patients who underwent a total of 324 TPE treatments showed that the INR and aPTT increased by 35.83% and 18.53%, respectively, in those treated with 5% albumin only. In patients who received a combination of 5% albumin and solvent/detergent-treated plasma, the changes in these coagulation parameters were considered to be of little or no clinical relevance. 13 Sigler et al. studied 63 procedures in pediatric patients who underwent TPE with 5% albumin and found that most patients had fibrinogen levels reduced below 100 mg/dL post TPE. Three patients had spontaneous bleeding complications (gastrointestinal, urinary catheter, apheresis catheter exit site) with pre-TPE fibrinogen levels above 250 mg/dL. They recommend that patients who undergo TPE with all 5% albumin replacement have a pre-fibrinogen level of at least 300 mg/dL, with the expectation that there will be a reduction of 57% to 79%, and if the pre-fibrinogen level is <300 mg/dL, they believe that one should consider the use of plasma in addition to 5% albumin replacement. They also state that a post-TPE fibrinogen level should be drawn to be aware of the increased risk of bleeding. 14 Additionally, the medical condition of the patient needs to be taken into account when considering the use of plasma for part or all of the replacement fluid, 5 either because the indication for apheresis dictates the use of plasma, as in TTP, or if there is clinical concern for bleeding, for example, the patient has alveolar hemorrhage, coagulopathy, recent surgery, and so forth.
In the case of a 70 kg patient who receives plasma as part of a TPE (eg, 10-15 mL/kg of plasma), approximately 700-1050 mL of plasma would be transfused, which equates to approximately three to five donor exposures. While not a major concern from the alloimmunization standpoint (HLA antigens are not appreciably present in plasma), there are a variety of infectious and non-infectious transfusion reactions that have been associated with the use of plasma, including transfusion-related acute lung injury (TRALI), the most common cause of transfusion-associated death in the United States for the last several years. 15 However, with the current strategy of using plasma predominantly from males 16 (or from females who have not been pregnant), reported TRALI cases have decreased. In patients who do not require daily TPE based on their clinical condition, an every-other-day TPE schedule would be expected to minimize the amount of plasma used for replacement fluid.
In contrast, although rare allergic or anaphylactic reactions have been reported for 5% albumin, which is a virally inactivated human-derived product, deaths from albumin infusion are very uncommon. Additionally, with current processing methodology, there have been no reports of viral or Creutzfeldt-Jakob transmission via albumin. 17 
| Extracorporeal circuit anticoagulation
To prevent clotting in the extracorporeal circuit, addition of an anticoagulant to the blood as it is drawn from the patient is necessary. The level of anticoagulation might need to be adjusted based on the patient's underlying medical condition (eg, cirrhosis, renal failure, or thrombocytopenia) or because the patient is already on an anticoagulant for an underlying condition and/or other extracorporeal circuit (eg, extracorporeal membrane oxygenation).
For some apheresis procedures, the operator has the option of using citrate or heparin as an anticoagulant for the extracorporeal circuit. In some cases, a combination of both citrate and heparin might be used. 18 Regardless of the anticoagulant used, attention must be paid to clinical signs or symptoms of active bleeding and laboratory values that could suggest the patient is at risk of hemorrhage.
In general, citrate is preferred over heparin because it is effective, has a shorter half-life (30-60 min), has a more favorable safety profile, and its effects can be reversed more rapidly (with calcium). Citrate binds to ionized calcium, an important co-factor in the clotting cascade. In patients who are sensitive to this effect, symptoms of acute hypocalcemia may be noted (eg, perioral numbness and tingling, metallic taste in the mouth, nausea, chills, muscle spasms). The incidence of these symptoms has been reported to occur in 1.5% to 9% of cases. 19 In unconscious patients, pediatric patients, or in those who do not alert caregivers to these early symptoms, more severe symptoms may occur (such as tetany, cardiac arrhythmias, and seizures). Slowing the rate of blood return or giving calcium [either via the oral or intravenous (IV) route] ordinarily resolves these problems. 20 Although citrate is mainly metabolized by the liver, it can be used safely in patients with liver cirrhosis. 21 Between 10% and 35% of a citrate load is excreted by the kidneys. The fractional excretion of citrate by the kidneys is markedly diminished with acidosis or hypokalemia and can be increased with high urine calcium or magnesium levels. 22 Citrate can be used safely in patients with acute renal failure, but because it can lead to a metabolic alkalosis, careful attention must be given to acid-base balance in this setting. 19 It is worth noting that anticoagulation by citrate is predominantly an in vitro effect; once the blood is returned to the patient, little systemic anticoagulation occurs. Patients who receive only citrate during TPE are unlikely to be at a significantly increased risk of bleeding due to interference with clotting factors. 6 The effect of citrate on circulating ionized calcium levels can be augmented depending on the type of replacement fluid that is used. Because plasma also contains citrate, increased symptoms due to citrate typically are seen in procedures that use plasma replacement fluid (eg, during treatment for TTP). Human 5% albumin is made relatively calcium poor during processing, and thus albumin replacement fluid readily binds ionized calcium and may augment some of the effects of citrate. Saline is the replacement fluid least likely to contribute to symptomatic hypocalcemia. 20 However, saline cannot be used exclusively as a replacement fluid, as only about a third of its volume will remain intravascular, thus predisposing the patient to hypotension. Citrate chelates circulating Ca 21 and Mg 21 . It is prudent to check serum ionized calcium and perhaps also magnesium levels prior to TPE procedures in patients at risk for citrate toxicity. Depending on these baseline values, the patient's underlying medical conditions, and the type of replacement fluid used, some facilities will automatically initiate replacement with IV calcium gluconate or calcium chloride and magnesium. For more stable patients, oral calcium carbonate might be given only if the patient experiences symptoms. Prophylactic and intraprocedural calcium may be prescribed for patients who experience citrate toxicity. Magnesium replacement is usually not needed; in an international survey of pediatric apheresis practice, 19% of respondents indicated that they used magnesium supplementation. 4 Heparin is inexpensive and has a short half-life (23 min to 2.48 h, see Table 1 ), but unlike citrate, its anticoagulant effect is active in vivo and it can contribute to clinically significant bleeding. For patients on warfarin therapy, sometimes the best choice is to change them to a continuous infusion of heparin. However, heparin introduces the potential for the patient to develop heparin induced thrombocytopenia (HIT). Patients who have a history of HIT should not be re-exposed to heparin if possible. In such cases, citrate is the best option. 23 
| Management of anticoagulants in patients undergoing TPE
Both inpatients and outpatients might be anticoagulated for a variety of medical conditions that are unrelated to their need for a TPE procedure (see Table 1 ). It is not uncommon for hospitalized patients to receive unfractionated heparin (UFH) or low molecular weight heparins (LMWHs) as prophylaxis for venous thromboembolism. Similarly, at the time of admission to the hospital, patients might be on LMWH, warfarin, or one of the newer direct oral anticoagulants (DOACs) because of a history of atrial fibrillation or another condition that might predispose them to clotting complications. The decision to place a central line and the timing of the apheresis procedure need to take each patient's risk of bleeding into consideration. In some cases, it might be wise to delay a procedure until the anticoagulant medication is no longer at therapeutic levels or can be reversed by an antagonist.
UFH can be given as a continuous infusion or by subcutaneous (SC) injections. 24, 25 It has the advantage of having a short half-life (less than 3 h). Some institutions represented by the authors withhold heparin infusions for at least 1 to 2 h before initiating TPE and then advise restarting the infusions 1 to 2 h after TPE has been completed. However, as heparin is removed during TPE, others actually recommend increasing the heparin drip rate during TPE. 26 Yet another option to consider is the possibility of decreasing the citrate to whole blood anticoagulation ratio in patients receiving heparin drips.
LMWHs have longer half-lives than UFH (eg, dalteparin [Fragmin®, 3 to 4 h half-life, once daily dosing] and enoxaparin [Lovenox ® , 7 h half-life, once or twice daily dosing]) and thus need to be withheld longer than UFH for TPEs. 27, 28 For patients receiving full therapeutic doses of these agents, it may be preferable for the dose to be held for 24 h prior to TPE; reversal with protamine sulfate generally is not recommended as long as the last LMWH dose was given at least 8 h before the procedure. A meta-analysis found that their efficacy and safety profiles did not vary significantly in patients of varying sizes (eg, in a comparison of patients of "normal" body weight to patients with "low" and "high" body weight). 30 However, no studies have been performed that specifically address the use of DOACs in patients undergoing TPE. Unfortunately, current standard coagulation tests are not very useful in defining bleeding risk with these drugs. For dabigatran, the use of a dilute thrombin time (TT) or ecarin-based assays are considered useful but are not widely used. For rivaroxaban, apixaban, and edoxaban, anti-Xa assays that have been calibrated to each specific agent are recommended but also are not widely used. For edoxaban, commercial calibrators for such an assay are not available.
For patients who experience active bleeding while on dabigatran a general recommendation is to check a TT. If it is normal, it is unlikely that a clinically significant dabigatran level is present. If it is elevated even slightly, it is likely that the drug is present and could be contributing to the bleeding episode. Similarly, for the Xa inhibitors, a normal anti-Xa assay most likely excludes clinically significant levels of the drug. An anti-Xa assay that is calibrated for the specific drug in use could be used to estimate the drug level, thus an anti-Xa assay that is calibrated only for heparin indicates the presence of the drug. 31 Although such recommendations are meant for bleeding episodes in patients taking DOACs, they could also be useful in assessing bleeding risks for patients taking DOACs who need to undergo emergency TPE procedures. Contraindications to the use of DOACs include renal or liver impairment and the use of medications known to inhibit or induce strong P-glycoprotein and CYP3A4. Examples of inhibitors include clarithromycin and ketoconazole; inducers include rifampin, phenytoin, and St. John's wort.
32,33
The DOACs have half-lives of 5-17 h, depending on the drug (see Table 1 ). The bleeding risks of performing apheresis procedures for patients anticoagulated with DOACs is not known. Withholding these drugs in the setting of apheresis requires careful consideration of the risk-benefit balance based on the specific indication for anticoagulation therapy. If a patient taking a DOAC is undergoing TPE and experiences a significant bleeding event, the treatment should be the same as for patients not undergoing apheresis who bleed while anticoagulated with DOACs. However, in the case of the patient on TPE, infusion of plasma may help to replace the coagulation factors removed during the TPE (unless plasma was used as a replacement fluid during the procedure).
Dabigatran has an FDA-approved antidote, Idarucizumab, a monoclonal antibody that binds and neutralizes the drug.
34-36
Reversal of Factor Xa inhibition with Andexanet alfa (AndexXa TM ) is currently the subject of clinical trials. In the meantime, if reversal is necessary for direct Factor Xa inhibitors, prothrombin complex concentrate (PCC), Factor Eight Inhibitor Bypassing Activity (FEIBA), or recombinant Factor VIIa (rFVIIa; NovoSeven ® ) may be attempted.
Fondaparinux (Arixtra   ®   ) , 37 a pentasaccharide indirect Factor Xa inhibitor, is administered by SC injection once a day. Its half-life ranges between 13 and 21 h. It is typically a bridge to longer term anticoagulation (eg, with warfarin) in patients with deep vein thrombosis or pulmonary embolism. If a patient taking fondaparinux experiences bleeding, recombinant Factor VIIa concentrate is recommended to reverse the effect. As previously noted, the anti-Xa assay calibrated specifically to fondaparinux is considered the best test for evaluating drug levels. 37 The direct thrombin inhibitors, argatroban 38 and bivalirudin (IV) 39 and desirudin (SC), 40 have short half-lives (see Table 1 ). If a patient is thought to be at an increased risk because of these agents, discontinuation of the agent should be enough to minimize the risk. 29, 38 Warfarin still is used commonly in patients with artificial heart valves and those at risk of stroke because of atrial fibrillation. Zantek et al. 41 found that the pre-procedure INR of patients on warfarin was predictive of the post-procedure INR when a one plasma volume TPE was performed using 5% albumin as the replacement fluid. They conducted 123 TPEs in patients on warfarin. There was 1 episode of oozing from the line site in a patient whose pre-TPE INR was 1.66. They concluded that the use of plasma or other coagulation support might not be needed in patients on warfarin who require TPE. 41 If there is concern for bleeding, and depending on the reason for the warfarin therapy, warfarin doses can be withheld, and/or the patient may be treated with vitamin K (if given IV, the INR should normalize within 6 to 12 h). If the patient is to be restarted on warfarin therapy after the procedure is completed, the lowest effective dose of vitamin K should be used; an oral dose of 2-2.5 mg may suffice for non-urgent situations, but 5-10 mg IV is recommended for emergent reversal. 42 Recent evidence suggests that IV administration of 5 mg of vitamin K can reduce the INR to <2 within 6 h, which might permit an urgent invasive procedure to be performed without the need for addition of PCC or plasma transfusion. 43 Alternatively, plasma can be used as part of the replacement fluid during the TPE, or the patient could be switched to UFH or LMWH before the procedure. 32, 44 Aspirin (acetylsalicylic acid) irreversibly inactivates cyclooxygenase, thus inhibiting prostaglandin synthesis and platelet aggregation. It has a half-life of 20-60 min, but its major active metabolite, salicylic acid, has a half-life of 6 h. It is prescribed most commonly in patients with a history of risk for cerebrovascular accident or coronary artery disease, and it might also be used in patients with atrial fibrillation and carotid artery stenosis. In individuals who are bleeding in the setting of platelet dysfunction from recent aspirin use, platelet transfusions may be considered prior to the initiation of TPE. [45] [46] [47] However, the PATCH study 47 demonstrated no benefit of platelet transfusion in the setting of spontaneous intracerebral hemorrhage, and the authors found that patients who received platelet transfusions in addition to standard care actually had worse outcomes than patients who received only standard care. Although prophylactic platelet transfusions have not been studied in the setting of TPE, this finding in patients with intracerebral hemorrhage should be considered when deciding whether or not to give platelets prophylactically prior to TPE. Before giving a platelet transfusion, it would be prudent to perform testing to assess platelet function (eg, by platelet mapping, platelet aggregation studies, thromboelastography, or use of the VerifyNow ® system). Non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen, naproxen, celecoxib, ketorolac) are similar to aspirin in that they inhibit prostaglandin synthesis and platelet aggregation, but their effect is reversible. They generally are used for pain relief in a variety of clinical situations and in the post-operative setting. In individuals who are experiencing bleeding or are at risk for bleeding from recent NSAID use, the best course, if safe, is waiting for this effect to fade. Platelet transfusion may be considered if there is active bleeding. 25 Oral platelet inhibitors are drugs that work by preventing platelet aggregation by blocking the P2Y 12 (ADP) receptor on the platelet surface. 48 Except for ticlopidine, which has a terminal elimination half-life of four to five days, the platelet inhibitors (clopidogrel, prasugrel, ticagrelor) have half-lives of about 6 to 9 h. They are used most commonly in patients who have coronary artery disease, especially those who have had coronary artery bypass grafting or percutaneous angioplasty with stenting, because of the risk of thrombosis (or re-thrombosis). They are administered orally with once or twice a day dosing, and patient compliance with them is generally good. Unfortunately, their use may increase the risk of bleeding complications in patients who undergo procedures that require anticoagulation, such as hemodialysis and apheresis. 45 Some drugs that might be used to offset the effects of platelet inhibitors include epsilon aminocaproic acid and tranexamic acid. Although it may seem intuitive that platelet transfusion may be helpful in reducing the extent of hemorrhage, a recent randomized study revealed that "platelet transfusion seems inferior to standard care for people taking antiplatelet therapy before intracerebral hemorrhage." 47 
| D IS C US S I ON
Our aim was to survey practices and review the pertinent literature with regard to the use of anticoagulants during TPEs. There are few published guidelines, and physicians coming into the field may not be aware of circumstances in which coagulation parameters need to be carefully adjusted and monitored. The results indicate that there is room for flexibility in practice, but it is important to be cognizant of the individual patient's clinical situation and to choose and adjust the available anticoagulants appropriately. We have pointed out some of the considerations needed to make judicious decisions in the care of these patients.
| C ONCL US I ONS
We have discussed the monitoring of coagulation in patients undergoing TPE who are on anticoagulant medications. The issues are often complex in individuals who may have underlying medical conditions that place them at high risk for bleeding or clotting. No single guideline applies to all situations, but, rather, patients must be monitored closely and managed on an individual basis taking into account their underlying medical condition, their medications, and other issues as presented above.
